About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Dose-ranging Study of Fluticasone Furoate (FF)

NCT01563029·139 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

GlaxoSmithKline

Age

5–11

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Written informed consent from at least one parent/ legal guardian to take part in the study.:
Diagnosis of asthma
pre-bronchodilator PEF between ≥50% to ≤90% of their best post-bronchodilator value
Receiving therapy of short acting beta-agonist (SABA) alone, LTM, or ICS (total daily dose \<FP 200mcg or equivalent)Exclusion :

You may not be if

history of life-threatening asthma
history of asthma exacerbation for asthma within 6 months prior to screening.
Culture-documented or suspected bacterial or viral infection
significant abnormality or medical condition
Present use of any tobacco products

The record

StatusCompleted

PhasePhase 2

Taking part597

StartedMar 2012

UpdatedMay 30, 2017

Conditions

Where139

GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Costa Mesa, California, United States
GSK Investigational Site
Huntington Beach, California, United States

Clareo Health | A Dose-ranging Study of Fluticasone Furoate (FF)